WO2017204445A3 - Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 - Google Patents

Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2017204445A3
WO2017204445A3 PCT/KR2017/002830 KR2017002830W WO2017204445A3 WO 2017204445 A3 WO2017204445 A3 WO 2017204445A3 KR 2017002830 W KR2017002830 W KR 2017002830W WO 2017204445 A3 WO2017204445 A3 WO 2017204445A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
active component
cancer prevention
containing same
alk protein
Prior art date
Application number
PCT/KR2017/002830
Other languages
English (en)
French (fr)
Other versions
WO2017204445A2 (ko
Inventor
황종연
하재두
김형래
조성윤
정희정
김필호
윤창수
이정옥
박지훈
Original Assignee
한국화학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국화학연구원 filed Critical 한국화학연구원
Publication of WO2017204445A2 publication Critical patent/WO2017204445A2/ko
Publication of WO2017204445A3 publication Critical patent/WO2017204445A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ALK 단백질의 분해를 유도하는 약물의 제조 방법 및 이를 유효성분으로 합유하는 암의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 화학식 1로 표시되는 화합물은 역형성 림프종 키나제(ALK)를 억제하거나 분해시킬 수 있어, 역형성 림프종 키나제(ALK) 관련 질환, 예를 들어 암의 예방 및 치료에 유용한 효과가 있다.
PCT/KR2017/002830 2016-05-24 2017-03-16 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 WO2017204445A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0063391 2016-05-24
KR1020160063391A KR101825065B1 (ko) 2016-05-24 2016-05-24 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2017204445A2 WO2017204445A2 (ko) 2017-11-30
WO2017204445A3 true WO2017204445A3 (ko) 2018-09-07

Family

ID=60411456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/002830 WO2017204445A2 (ko) 2016-05-24 2017-03-16 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Country Status (2)

Country Link
KR (1) KR101825065B1 (ko)
WO (1) WO2017204445A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109422733A (zh) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物
KR102538307B1 (ko) * 2017-12-13 2023-05-31 상하이테크 유니버시티 Alk 단백질 분해제 및 암 치료에서의 이의 용도
CN110684015A (zh) * 2018-07-06 2020-01-14 四川大学 靶向alk的protac及其应用
JPWO2020027225A1 (ja) 2018-07-31 2021-11-11 ファイメクス株式会社 複素環化合物
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
KR20200024669A (ko) 2018-08-28 2020-03-09 한국화학연구원 표적 단백질의 분해를 유도하기 위한 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 표적 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
EP3922632A4 (en) 2019-02-07 2023-02-15 Korea Research Institute of Chemical Technology DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE
EP4029499A4 (en) * 2019-06-12 2023-07-26 Shanghaitech University ALK PROTEIN REGULATOR AND ITS ANTITUMOR APPLICATION
KR20210016103A (ko) 2019-07-31 2021-02-15 주식회사 온코빅스 Alk 단백질의 분해를 유도하는 신규 화합물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
CN110878095B (zh) * 2019-12-02 2023-01-24 中山大学 一种姜黄素双功能分子及其制备方法和应用
CN111454327A (zh) * 2020-04-02 2020-07-28 中国人民解放军第二军医大学 一种nampt蛋白降解靶向嵌合体及其制备方法和应用
US20230265116A1 (en) * 2020-07-16 2023-08-24 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
BR112023004497A2 (pt) * 2020-09-11 2023-04-04 J2H Biotech Inc Composto de fórmula química 1 ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica para o tratamento ou prevenção de câncer com uma mutação de egfr
US20240165243A1 (en) * 2021-02-10 2024-05-23 Beigene Switzerland Gmbh Egfr degraders and methods of use
CN116940581A (zh) * 2021-05-19 2023-10-24 和径医药科技（上海）有限公司 一类新型蛋白降解剂及其应用
WO2022251588A1 (en) * 2021-05-27 2022-12-01 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
EP4361163A1 (en) 2021-06-25 2024-05-01 Jing Medicine Technology (Shanghai) Ltd. Protein inhibitor or degrading agent, pharmaceutical composition containing same and pharmaceutical use
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150010935A (ko) * 2012-01-12 2015-01-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150010935A (ko) * 2012-01-12 2015-01-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FISCHER, E. S. ET AL.: "Structure of the DDB 1-CRBN E3 Ubiquitin Ligase in Complex with Thalidomide", NATURE, vol. 512, 2014, pages 49 - 53, XP055531429 *
HWANG, J. Y. ET AL.: "Targeted Degradation of Anaplastic Lymphoma Kinase by Target Degraducer in Non-small Cell Lung Cancer", ANNALS OF ONCOLOGY, vol. 27, no. 9, December 2016 (2016-12-01) *
LAI, A. C. ET AL.: "Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL", ANGEWANDTE CHEMIE INTERNATIONALEDITION, vol. 55, no. 2, January 2016 (2016-01-01), pages 807 - 810, XP055388339 *
TOURE, M. ET AL.: "Small-Molecule PROTACS: New Approaches to Protein Degradation", ANGEWANDTE CHEMIE INTERNATIONAL EITION, vol. 55, no. 6, February 2016 (2016-02-01), pages 1966 - 1973, XP055546470 *
WANG, P. ET AL.: "Synthesis and Anticancer Activities of Ceritinib Analogs Modified in the Terminal Piperidine Ring", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 93, 2015, pages 1 - 8, XP029176720 *

Also Published As

Publication number Publication date
KR20170132934A (ko) 2017-12-05
KR101825065B1 (ko) 2018-02-05
WO2017204445A2 (ko) 2017-11-30

Similar Documents

Publication Publication Date Title
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CR20220066A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
AU2018231032A8 (en) JAK inhibitors containing a 4-membered heterocyclic amide
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
MY201925A (en) Macrocyclic compounds and uses thereof
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12017502363A1 (en) Brk inhibitory compound
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
NZ761519A (en) Nlrp3 modulators
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006520A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12020550252A1 (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2019006941A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17802964

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17802964

Country of ref document: EP

Kind code of ref document: A2